BriaCell Therapeutics Corp.

TSX:BCT.TO

Biotechnology

Healthcare
$5.75 +18.88%

+$0.94 today

Market cap
$50.02M
Beta
1.53
P/E (TTM)
-0.3
EPS (TTM)
-$4.23
52W Low $3.68High $20.40

Volume 0.00M

Average 0.01M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$28.51M

FY 2025 · Annual

Investing Cash Flow

-$7.74M

FY 2025 · Annual

Financing Cash Flow

$46.00M

FY 2025 · Annual

+941.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Net Income(13.82M)(26.84M)(20.3M)(4.93M)(26.63M)
Depreciation & Amortization15.26K15.27K15.27K83.9K107.93K
Deferred Income Tax00000
Stock-Based Compensation1.97M3.07M2.19M1.8M0
Change in Working Capital(2.28M)(391.29K)(3.53M)7.05M(1.93M)
Accounts Receivables9.94K(11.53K)5.23K(732.58K)742.6K
Inventory00000
Accounts Payables(1.41M)249.16K660.46K6.05M(3.93M)
Other Working Capital(886.38K)(628.93K)(4.2M)1.74M1.26M
Other Non-Cash Items6.36M11.66M(2.12M)(28.14M)(58.73K)
Operating Cash Flow(7.75M)(12.48M)(23.74M)(24.13M)(28.51M)
Capital Expenditures000(456.8K)0
Acquisitions (Net)000(225K)0
Purchases of Investments0000(7.74M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(681.8K)(7.74M)
Debt Repayment(330.4K)0000
Common Stock Issued51.62M04M4.42M46M
Common Stock Repurchased0(10.17M)(47.29K)00
Dividends Paid00000
Other Financing Activities13.71M6.43M1.59K00
Financing Cash Flow65M(3.74M)3.95M4.42M46M
Effect of Forex Changes0000(84.08K)
Net Change in Cash57.25M(16.23M)(19.79M)(20.39M)9.67M
Free Cash Flow(7.75M)(12.48M)(23.74M)(24.58M)(28.51M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$26.6M
+ D&A$107.9K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$1.9M
- Other Non-Cash-$58.7K
= Operating Cash Flow-$28.5M
- Capex$0
= Free Cash Flow-$28.5M

Analysis

FY2025 free cash flow is -$28.5M. FCF conversion is 107.1% of net income. Operating cash flow was -$28.5M, with capex of $0. The largest bridge item is Working Capital at -$1.9M.

Competitors

Peer companies in the same sector

Health

No competitor data available.

Recent Filings

Recent regulatory filings

No filings found.

Does BCT.TO generate free cash flow?

BriaCell Therapeutics Corp. (BCT.TO) generated -$28.51M of free cash flow in fiscal 2025.

How much operating cash flow does BCT.TO produce?

Operating cash flow was -$28.51M, before capital expenditures of $0.00.